Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + ivonescimab
- Development stage
- Phase 2
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + ivonescimab is an investigational combination therapy being evaluated for the treatment of advanced non-small cell lung cancer (NSCLC). Ivonescimab (also known as AK112 or SMT-112) is a humanized bispecific monoclonal antibody that concurrently targets Programmed Cell Death Protein 1 (PD-1) and Vascular Endothelial Growth Factor (VEGF), designed to promote anti-tumor immune responses while inhibiting angiogenesis within the tumor microenvironment. Gemcitabine is a pyrimidine antimetabolite chemotherapy agent that inhibits DNA synthesis and has demonstrated potential immunostimulatory effects, such as increasing T-cell infiltration and reducing immunosuppressive cell populations. This combination is currently being studied in the Phase II ORIGIN2 trial (SAKK 18/25), sponsored by the Swiss Cancer Institute (SAKK), specifically for patients whose disease has progressed following prior chemoimmunotherapy.
- Other names
- gemcitabine plus ivonescimab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on gemcitabine + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + ivonescimab.